title: A pivot mutation impedes reverse evolution across an adaptive landscape for drug resistance in Plasmodium vivax.
abstract: BACKGROUND
  The study of reverse evolution from resistant to susceptible phenotypes can reveal constraints on biological evolution, a topic for which evolutionary theory has relatively few general principles. The public health catastrophe of antimicrobial resistance in malaria has brought these constraints on evolution into a practical realm, with one proposed solution: withdrawing anti-malarial medication use in high resistance settings, built on the assumption that reverse evolution occurs readily enough that populations of pathogens may revert to their susceptible states. While past studies have suggested limits to reverse evolution, there have been few attempts to properly dissect its mechanistic constraints.
  
  
  METHODS
  Growth rates were determined from empirical data on the growth and resistance from a set of combinatorially complete set of mutants of a resistance protein (dihydrofolate reductase) in Plasmodium vivax, to construct reverse evolution trajectories. The fitness effects of individual mutations were calculated as a function of drug environment, revealing the magnitude of epistatic interactions between mutations and genetic backgrounds. Evolution across the landscape was simulated in two settings: starting from the population fixed for the quadruple mutant, and from a polymorphic population evenly distributed between double mutants.
  
  
  RESULTS
  A single mutation of large effect (S117N) serves as a pivot point for evolution to high resistance regions of the landscape. Through epistatic interactions with other mutations, this pivot creates an epistatic ratchet against reverse evolution towards the wild type ancestor, even in environments where the wild type is the most fit of all genotypes. This pivot mutation underlies the directional bias in evolution across the landscape, where evolution towards the ancestor is precluded across all examined drug concentrations from various starting points in the landscape.
  
  
  CONCLUSIONS
  The presence of pivot mutations can dictate dynamics of evolution across adaptive landscape through epistatic interactions within a protein, leaving a population trapped on local fitness peaks in an adaptive landscape, unable to locate ancestral genotypes. This irreversibility suggests that the structure of an adaptive landscape for a resistance protein should be understood before considering resistance management strategies. This proposed mechanism for constraints on reverse evolution corroborates evidence from the field indicating that phenotypic reversal often occurs via compensatory mutation at sites independent of those associated with the forward evolution of resistance. Because of this, molecular methods that identify resistance patterns via single SNPs in resistance-associated markers might be missing signals for resistance and compensatory mutation throughout the genome. In these settings, whole genome sequencing efforts should be used to identify resistance patterns, and will likely reveal a more complicated genomic signature for resistance and susceptibility, especially in settings where anti-malarial medications have been used intermittently. Lastly, the findings suggest that, given their role in dictating the dynamics of evolution across the landscape, pivot mutations might serve as future targets for therapy.
authors.affiliation: Department of Biology, University of Vermont, Burlington, VT, USA. bogbunug@uvm.edu.|Vermont Complex Systems Center, The University of Vermont, Burlington, VT, USA. bogbunug@uvm.edu.
authors.forename: C Brandon
authors.initials: CB
authors.lastname: Ogbunugafor
authors.affiliation: Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA. dhartl@oeb.harvard.edu.
authors.forename: Daniel
authors.initials: D
authors.lastname: Hartl
mesh_terms: D000962:Antimalarials / Q000627:therapeutic use*; D005075:Biological Evolution; D004351:Drug Resistance / Q000235:genetics; D009154:Mutation; D010966:Plasmodium vivax / Q000187:drug effects / Q000235:genetics*; D015800:Protozoan Proteins / Q000235:genetics*; D011739:Pyrimethamine / Q000627:therapeutic use; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics
chemical_list: D000962:Antimalarials; D015800:Protozoan Proteins; D013762:Tetrahydrofolate Dehydrogenase; D011739:Pyrimethamine
references.citation: Drug Resist Updat. 2005 Feb-Apr;8(1-2):43-50
references.pmid: 15939341
references.citation: Nat Rev Microbiol. 2010 Apr;8(4):260-71
references.pmid: 20208551
references.citation: Science. 2006 Apr 7;312(5770):111-4
references.pmid: 16601193
references.citation: Antimicrob Agents Chemother. 2005 Sep;49(9):3601-6
references.pmid: 16127028
references.citation: Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14494-9
references.pmid: 25246554
references.citation: PLoS Pathog. 2014 Jun 26;10(6):e1004225
references.pmid: 24968123
references.citation: Nat Genet. 2012 Sep;44(9):1046-50
references.pmid: 22863733
references.citation: Proc Biol Sci. 2014 Nov 7;281(1794):20140566
references.pmid: 25253451
references.citation: Malar J. 2014 Apr 19;13:150
references.pmid: 24745605
references.citation: Proc Natl Acad Sci U S A. 2011 Jun 28;108 Suppl 2:10871-7
references.pmid: 21690376
references.citation: Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11672-7
references.pmid: 26261345
references.citation: Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12025-30
references.pmid: 19587242
references.citation: J Hist Biol. 1970 Fall;3:189-212
references.pmid: 11609651
references.citation: Antimicrob Agents Chemother. 2001 Nov;45(11):3122-7
references.pmid: 11600366
references.citation: Mol Biochem Parasitol. 1998 May 1;92(2):265-73
references.pmid: 9657331
references.citation: Am J Trop Med Hyg. 2009 Sep;81(3):525-8
references.pmid: 19706926
references.citation: PLoS Comput Biol. 2006 Oct;2(10):e137
references.pmid: 17040124
references.citation: Clin Infect Dis. 2007 Jan 15;44(2):159-77
references.pmid: 17173212
references.citation: Mol Biol Evol. 2010 Dec;27(12):2682-90
references.pmid: 20576759
references.citation: Curr Opin Genet Dev. 2013 Dec;23(6):700-7
references.pmid: 24290990
references.citation: Wiad Parazytol. 2011;57(2):87-92
references.pmid: 21682092
references.citation: Nat Genet. 2011 Dec 18;44(1):101-5
references.pmid: 22179135
references.citation: PLoS Pathog. 2013 Sep;9(9):e1003578
references.pmid: 24068922
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2581-7
references.pmid: 15215112
references.citation: J Mol Evol. 2013 Sep;77(3):81-91
references.pmid: 24071997
references.citation: J Infect Dis. 2003 Jun 15;187(12):1870-5
references.pmid: 12792863
references.citation: J Antimicrob Chemother. 2011 Jun;66(6):1223-30
references.pmid: 21460369
references.citation: PLoS Genet. 2007 Mar 23;3(3):e47
references.pmid: 17381243
references.citation: Am J Trop Med Hyg. 2009 Jul;81(1):19-22
references.pmid: 19556560
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13285-90
references.pmid: 15308772
references.citation: N Engl J Med. 1997 Aug 14;337(7):441-6
references.pmid: 9250845
references.citation: J Antimicrob Chemother. 2010 Feb;65(2):350-60
references.pmid: 19900952
references.citation: Am Fam Physician. 2014 Jun 15;89(12):938-41
references.pmid: 25162160
references.citation: Genetics. 2000 Mar;154(3):985-97
references.pmid: 10757748
references.citation: PLoS One. 2013;8(2):e56040
references.pmid: 23418506
references.citation: Antimicrob Resist Infect Control. 2012 Feb 14;1(1):11
references.pmid: 22958833
references.citation: Mol Microbiol. 2013 May;88(4):702-12
references.pmid: 23347134
references.citation: Am J Trop Med Hyg. 2006 Oct;75(4):617-21
references.pmid: 17038682
references.citation: Am J Trop Med Hyg. 2010 Sep;83(3):474-9
references.pmid: 20810806
references.citation: Sci Transl Med. 2013 Sep 25;5(204):204ra132
references.pmid: 24068739
references.citation: Nature. 2007 Jan 25;445(7126):383-6
references.pmid: 17251971
references.citation: J Antimicrob Chemother. 2012 Feb;67(2):367-74
references.pmid: 22086859
references.citation: Nature. 2009 Sep 24;461(7263):515-9
references.pmid: 19779450
references.citation: Ann Intern Med. 2003 Sep 16;139(6):483-7
references.pmid: 13679325
references.citation: Bull World Health Organ. 1982;60(1):115-22
references.pmid: 6979415
references.citation: Am J Trop Med Hyg. 2010 Dec;83(6):1206-11
references.pmid: 21118923
references.citation: FEMS Microbiol Rev. 2011 Sep;35(5):901-11
references.pmid: 21707669
references.citation: Infect Genet Evol. 2012 Jan;12(1):38-44
references.pmid: 22020253
references.citation: Phys Rev Lett. 2011 May 13;106(19):198102
references.pmid: 21668204
references.citation: J Genet. 2011 Aug;90(2):187-90
references.pmid: 21869466
references.citation: Malar J. 2006 Jul 03;5:54
references.pmid: 16817953
references.citation: Trop Med Parasitol. 1990 Sep;41(3):268-72
references.pmid: 2255843
references.citation: Am J Trop Med Hyg. 2005 Mar;72(3):267-72
references.pmid: 15772319
references.citation: Lancet Infect Dis. 2008 Feb;8(2):125-32
references.pmid: 18222163
references.citation: Trans R Soc Trop Med Hyg. 2006 Sep;100(9):831-7
references.pmid: 16513151
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4233-40
references.pmid: 18809933